Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary Skrivanek

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Genetic Epidemiology|November 26, 2003
Haplotyping using SIMPLE: caution on ignoring interferenceShili Lin, Zachary Skrivanek, Mark Irwin
Genetic Epidemiology|June 19, 2003
Linkage analysis with sequential imputationZachary Skrivanek, Shili Lin, Mark Irwin
Journal of Diabetes Science and Technology|January 9, 2013
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristicsMary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, et al.
Diabetes Care|April 19, 2014
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)Michael Nauck, Ruth S Weinstock, Guillermo E Umpierrez, et al.
Diabetes Care|February 26, 2015
Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158Michael Nauck, Ruth S Weinstock, Guillermo E Umpierrez, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 studyKimberly Spencer, Kelly Colvin, Brad Braunecker, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Genetic Epidemiology|November 26, 2003
Haplotyping using SIMPLE: caution on ignoring interferenceShili Lin, Zachary Skrivanek, Mark Irwin
Genetic Epidemiology|June 19, 2003
Linkage analysis with sequential imputationZachary Skrivanek, Shili Lin, Mark Irwin
Journal of Diabetes Science and Technology|January 9, 2013
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristicsMary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, et al.
Diabetes Care|April 19, 2014
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)Michael Nauck, Ruth S Weinstock, Guillermo E Umpierrez, et al.
Diabetes Care|February 26, 2015
Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158Michael Nauck, Ruth S Weinstock, Guillermo E Umpierrez, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 studyKimberly Spencer, Kelly Colvin, Brad Braunecker, et al.
Pageof 1